Last reviewed · How we verify
HM15275
At a glance
| Generic name | HM15275 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus (PHASE2)
- A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HM15275 CI brief — competitive landscape report
- HM15275 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI